Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
J Natl Cancer Inst
    April 2026
  1. GAWDI R, Sjolander EN, Lee JS, Whelan RL, et al
    Evaluating the role of medicaid expansion on survival in early onset colorectal cancer.
    J Natl Cancer Inst. 2026 Apr 6:djag109. doi: 10.1093.
    >> Share

  2. CAMPOY S, Drouet Y, Rochefort P, Bonadona V, et al
    Cancer risks in Lynch syndrome carriers: a systematic review and meta-analysis.
    J Natl Cancer Inst. 2026;118:589-602.
    >> Share

    March 2026
  3. CHIA BJ, Allegra C, Krishnamurthi S, Lieu C, et al
    A framework to evaluate surrogate endpoints at the trial level: Analysis in colorectal cancer.
    J Natl Cancer Inst. 2026 Mar 23:djag088. doi: 10.1093.
    >> Share

  4. PISCITELLO AJ, Edwards V DK, Fransen S, Meester RGS, et al
    RE: the centers for medicare and medicaid services and others misunderstand stool testing for colorectal cancer.
    J Natl Cancer Inst. 2026 Mar 17:djag074. doi: 10.1093.
    >> Share

  5. OPHOFF D, Bos D, van Heek T, Witteman BJ, et al
    Liver fat and clinical outcomes in individuals with stage I-III colon or rectal cancer.
    J Natl Cancer Inst. 2026;118:466-475.
    >> Share

  6. BRENNER H, Holland-Letz T, Kopp-Schneider A, Heisser T, et al
    Early-detection and prevention effects of screening sigmoidoscopy: evidence from randomized trials revisited.
    J Natl Cancer Inst. 2026;118:422-428.
    >> Share

    February 2026

  7. Correction to: Changing paradigms in colorectal cancer screening.
    J Natl Cancer Inst. 2026 Feb 17:djag010. doi: 10.1093.
    >> Share

  8. HUANG BZ, Chen F, Bogumil D, Han S, et al
    Interaction of genetic and lifestyle risk scores on colorectal cancer risk across five racial and ethnic populations.
    J Natl Cancer Inst. 2026 Feb 16:djag045. doi: 10.1093.
    >> Share

  9. RUTTER CM, Maerzluft CE, Matrajt L, Nascimento de Lima P, et al
    CRC-SPIN version 3.0: an updated policy model for colorectal cancer screening that includes the serrated pathway.
    J Natl Cancer Inst. 2026 Feb 16:djag037. doi: 10.1093.
    >> Share

  10. YASINZAI AQK, Jalali P, Syaj S, Sahin IH, et al
    Trends and projected burden of early-onset gastrointestinal malignancies in the United States: a population-based analysis (2001-2021).
    J Natl Cancer Inst. 2026;118:250-260.
    >> Share

    January 2026
  11. COURNEYA KS, Booth CM, Vardy JL, Friedenreich CM, et al
    Effects of a structured exercise program on motivational outcomes in patients with Colon cancer.
    J Natl Cancer Inst. 2026 Jan 29:djag023. doi: 10.1093.
    >> Share

  12. PINSKY PF
    Endoscopic screening for colorectal cancer: efficacy versus effectiveness.
    J Natl Cancer Inst. 2026 Jan 20:djaf384. doi: 10.1093.
    >> Share

  13. LIEBERMAN D
    Centers for Medicare and Medicaid and colorectal cancer screening test standards: time for a change.
    J Natl Cancer Inst. 2026 Jan 16:djaf367. doi: 10.1093.
    >> Share

  14. SHAUKAT A, Meng Z, Kutnik K, Sun CK, et al
    Age- and sex-adjusted performance of a colorectal cancer screening test using US census distribution.
    J Natl Cancer Inst. 2026 Jan 9:djag007. doi: 10.1093.
    >> Share

  15. WESTVOLD SJ, Long JB, Fan J, Kc M, et al
    Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.
    J Natl Cancer Inst. 2026;118:130-140.
    >> Share

  16. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
    Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
    J Natl Cancer Inst. 2026;118:94-101.
    >> Share

    December 2025
  17. YU Z
    RE: a prediction model for metachronous colorectal cancer: development and validation.
    J Natl Cancer Inst. 2025 Dec 13:djaf351. doi: 10.1093.
    >> Share

  18. BOIGE V, Menoret E, Le Teuff G, Boyer JC, et al
    A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.
    J Natl Cancer Inst. 2025 Dec 12:djaf357. doi: 10.1093.
    >> Share

  19. CORONADO GD, Hoffman RM, Llavona-Ortiz J, Rutter CM, et al
    The Centers for Medicare and Medicaid Services and others misunderstand stool testing for colorectal cancer.
    J Natl Cancer Inst. 2025 Dec 1:djaf341. doi: 10.1093.
    >> Share

    November 2025
  20. WU T, Ou Q, Xu H, Chen Y, et al
    Prediagnostic dietary phytosterol intake, inflammatory biomarkers, and colorectal cancer survival: a cohort study.
    J Natl Cancer Inst. 2025 Nov 10:djaf325. doi: 10.1093.
    >> Share

  21. CHEN KL, Mangione CM, Shih YT
    Unmet social needs and colorectal cancer testing at 45-49 since the 2021 USPSTF recommendation.
    J Natl Cancer Inst. 2025 Nov 9:djaf318. doi: 10.1093.
    >> Share

  22. LIU Q, Wiese D, Pinheiro PS, Bispo JB, et al
    Association between racialized economic segregation and stage at diagnosis for 3 screenable cancers in New York City.
    J Natl Cancer Inst. 2025;117:2259-2271.
    >> Share

    October 2025
  23. ZHAO Y, Nogueira MS, Milne GL, Gao YT, et al
    Time-dependent relationship between urinary biomarkers of nucleic acid oxidation and colorectal cancer risk.
    J Natl Cancer Inst. 2025 Oct 31:djaf312. doi: 10.1093.
    >> Share

  24. BASU P
    Changing paradigms in colorectal cancer screening.
    J Natl Cancer Inst. 2025 Oct 11:djaf267. doi: 10.1093.
    >> Share

  25. MEESTER RGS, Piscitello AJ, Duimstra JA, Liang PS, et al
    Comparative benefits, burdens and harms of emerging blood-based tests for colorectal cancer screening.
    J Natl Cancer Inst. 2025 Oct 6:djaf277. doi: 10.1093.
    >> Share

  26. EBNER DW, Fendrick AM, Kisiel JB, Estes C, et al
    Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies.
    J Natl Cancer Inst. 2025 Oct 1:djaf209. doi: 10.1093.
    >> Share

  27. EBNER DW, Estes C, Limburg PJ
    RE: Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies.
    J Natl Cancer Inst. 2025 Oct 1:djaf266. doi: 10.1093.
    >> Share

  28. BRAY F, Laversanne M
    Stat Bite: recent trends in colon cancer incidence at ages 25-49 vs 50-74 in 50 countries.
    J Natl Cancer Inst. 2025;117:2146-2147.
    >> Share

  29. IFHAM HANIF M, Sholihah MM
    RE: Effects of a high-fiber, high-fruit, and high-vegetable, low-fat dietary intervention on the rectal tissue microbiome.
    J Natl Cancer Inst. 2025;117:2142-2143.
    >> Share

    September 2025
  30. CHENG E, Shi Q, Shields AF, Xue X, et al
    Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance).
    J Natl Cancer Inst. 2025 Sep 25:djaf281. doi: 10.1093.
    >> Share

  31. MEESTER RGS, Miller EA, Pinsky PF, Schoen RE, et al
    Contrasts in colorectal cancer incidence and mortality in screening trials of sigmoidoscopy versus colonoscopy (NordICC).
    J Natl Cancer Inst. 2025 Sep 14:djaf269. doi: 10.1093.
    >> Share

  32. HAAS JS, Todd KW, Mclerran D, Tiro JA, et al
    Gaps in care across the cancer screening continuum for cervical, colorectal and lung cancer.
    J Natl Cancer Inst. 2025 Sep 10:djaf248. doi: 10.1093.
    >> Share

  33. KOKER G, Ozcelik G
    RE: Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women.
    J Natl Cancer Inst. 2025 Sep 3:djaf252. doi: 10.1093.
    >> Share

  34. KAZEMIAN E, Mo Q, Matejcic M, Tsai YY, et al
    Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer.
    J Natl Cancer Inst. 2025 Sep 1:djaf140. doi: 10.1093.
    >> Share

    August 2025
  35. DOWNHAM L, Laversanne M, Perdomo S, Filho AM, et al
    Increase of early-onset colorectal cancer: a cohort effect.
    J Natl Cancer Inst. 2025 Aug 23:djaf238. doi: 10.1093.
    >> Share

  36. MAJOR A, Chou J, Lam H, Kim KE, et al
    Mortality after colorectal cancer among survivors of childhood cancer.
    J Natl Cancer Inst. 2025 Aug 21:djaf127. doi: 10.1093.
    >> Share

  37. ZAANAN A, Bergen ES, Evesque L, Meurisse A, et al
    Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study.
    J Natl Cancer Inst. 2025 Aug 20:djaf229. doi: 10.1093.
    >> Share

  38. DUHOKY R, Geitenbeek RTJ, Niccolo Piozzi G, Burghgraef TA, et al
    Ten years of robot-assisted versus laparoscopic total mesorectal excision for rectal cancer (short-term RESOLUTION).
    J Natl Cancer Inst. 2025;117:1614-1626.
    >> Share

  39. FULLER S, Alexeeff S, Caan B, Goncalves MD, et al
    Early identification of weight loss trajectories in advanced cancer and associations with survival.
    J Natl Cancer Inst. 2025;117:1729-1732.
    >> Share

    July 2025
  40. NASCIMENTO DE LIMA P, Bartholomew L, May FP, Coronado GD, et al
    The triple-effect of colorectal cancer screening: reducing deaths, government spending and mortality disparities.
    J Natl Cancer Inst. 2025 Jul 30:djaf202. doi: 10.1093.
    >> Share

  41. ZHANG Y, Karahalios A, Win AK, Makalic E, et al
    A prediction model for metachronous colorectal cancer: development and validation.
    J Natl Cancer Inst. 2025 Jul 16:djaf191. doi: 10.1093.
    >> Share

  42. LIEBERMAN D, Ladabaum U
    Non-invasive colorectal cancer screening: simple may be optimal.
    J Natl Cancer Inst. 2025 Jul 7:djaf171. doi: 10.1093.
    >> Share

  43. XU J, Lou T, Xu L
    RE: Post-diagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis.
    J Natl Cancer Inst. 2025 Jul 4:djaf168. doi: 10.1093.
    >> Share

  44. HUANG YJ, Lin JA, Chen WM, Shia BC, et al
    Metformin use and risk of colorectal cancer in patients with inflammatory bowel disease: a nationwide, Population-Based cohort study.
    J Natl Cancer Inst. 2025 Jul 2:djaf165. doi: 10.1093.
    >> Share

  45. ALVAREZ J, Zambare W, George M, Garcia R, et al
    Utilizing Patient Input in Rectal Cancer Trial Design.
    J Natl Cancer Inst. 2025;117:1421-1428.
    >> Share

  46. BLEYER A, Ries LAG, Cameron DB, Mansfield SA, et al
    Colon, colorectal, and all cancer incidence increase in the young due to appendix reclassification.
    J Natl Cancer Inst. 2025;117:1340-1349.
    >> Share

  47. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
    Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2025;117:1506-1511.
    >> Share

    June 2025
  48. HARLASS M, Knudsen AB, Nieboer D, van Duuren LA, et al
    Benefits of colorectal cancer screening using FIT with varying positivity thresholds by age and sex.
    J Natl Cancer Inst. 2025 Jun 23:djaf149. doi: 10.1093.
    >> Share

  49. ZAMAN FY, Orchard SG, Polekhina G, Gibbs P, et al
    Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults.
    J Natl Cancer Inst. 2025 Jun 14:djaf145. doi: 10.1093.
    >> Share

  50. YARMOLINSKY J, Lee MA, Lau E, Moratalla-Navarro F, et al
    Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention.
    J Natl Cancer Inst. 2025 Jun 13:djaf137. doi: 10.1093.
    >> Share

  51. OVEISI N, Sayre EC, Brotto LA, Cheng V, et al
    Sexual health outcomes after colorectal cancer diagnosis in females: a population-based cohort study.
    J Natl Cancer Inst. 2025 Jun 1:djaf120. doi: 10.1093.
    >> Share

  52. BYRD DA, Gomez M, Hogue S, Wan Y, et al
    Effects of a high-fiber, high-fruit and high-vegetable, low-fat dietary intervention on the rectal tissue microbiome.
    J Natl Cancer Inst. 2025;117:1237-1244.
    >> Share

    May 2025

  53. Correction to: Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2025 May 30:djaf124. doi: 10.1093.
    >> Share

  54. CHAR SK, Chan JA, Ng K
    Rising incidence of early-onset colorectal cancer: impact of anatomy and histology.
    J Natl Cancer Inst. 2025 May 29:djaf094. doi: 10.1093.
    >> Share

  55. CHEN QY, Keum N, Giovannucci EL
    Post-diagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis.
    J Natl Cancer Inst. 2025 May 2:djaf098. doi: 10.1093.
    >> Share

  56. SOERJOMATARAM I, Bardot A, Bray F
    Stat Bite: Surviving or dying from colon cancer or other causes 5 years after diagnosis, Australia 2010-2014, females.
    J Natl Cancer Inst. 2025;117:1090-1091.
    >> Share

    April 2025
  57. TSEGAYE AT, Shing JZ, Vo JB, Kreimer AR, et al
    Racial and ethnic differences in HPV-related cancer incidence in the United States, 2001-2020.
    J Natl Cancer Inst. 2025 Apr 26:djaf107. doi: 10.1093.
    >> Share

  58. MURPHY CC, Dias EM, Cirillo PM, Krigbaum NY, et al
    Father's occupation and colorectal cancer in his adult offspring.
    J Natl Cancer Inst. 2025 Apr 24:djaf104. doi: 10.1093.
    >> Share

  59. KUMAR R, Hallemeier CL, Chang DT, Lu SE, et al
    Increased occurrence of malignancy before and after chemoradiation for anal squamous cell carcinoma: a multi-institutional analysis.
    J Natl Cancer Inst. 2025;117:772-780.
    >> Share

  60. SANTUCCI C, Mignozzi S, Alicandro G, Pizzato M, et al
    Trends in cancer mortality under age 50 in 15 upper-middle and high-income countries.
    J Natl Cancer Inst. 2025;117:747-760.
    >> Share

    February 2025
  61. LIU Y, Song M, Giovannucci EL, Platz EA, et al
    Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study.
    J Natl Cancer Inst. 2025 Feb 25:djaf046. doi: 10.1093.
    >> Share

  62. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    >> Share

  63. TROESTER A, Parikh R, Southwell B, Ester E, et al
    Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review.
    J Natl Cancer Inst. 2025;117:240-252.
    >> Share

    January 2025
  64. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
    NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
    J Natl Cancer Inst. 2025;117:120-133.
    >> Share

    December 2024
  65. HU Q, Yang X, Sun Y
    Re: Characteristics of a cost-effective blood test for colorectal cancer screening.
    J Natl Cancer Inst. 2024 Dec 24:djae340. doi: 10.1093.
    >> Share

  66. LI X, Hur J, Zhang Y, Song M, et al
    Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women.
    J Natl Cancer Inst. 2024 Dec 17:djae330. doi: 10.1093.
    >> Share

    November 2024
  67. JUDGE SJ, Malekzadeh P, Corines MJ, Gollub MJ, et al
    Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy.
    J Natl Cancer Inst. 2024;116:1761-1766.
    >> Share

    October 2024
  68. DOWNIE JM, Joshi AD, Geraghty CM, Guercio BJ, et al
    Novel metabolomic predictors of incident colorectal cancer in men and women.
    J Natl Cancer Inst. 2024 Oct 28:djae270. doi: 10.1093.
    >> Share

  69. HU Q, Zhou X, Sun Y
    RE: Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).
    J Natl Cancer Inst. 2024 Oct 16:djae257. doi: 10.1093.
    >> Share

  70. VAN DEN PUTTELAAR R, Shi KS, Smith R, Zhao J, et al
    Implications of the initial braidwood v. Becerra ruling for colorectal cancer outcomes: a modeling study.
    J Natl Cancer Inst. 2024 Oct 3:djae244. doi: 10.1093.
    >> Share

  71. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    >> Share

    September 2024
  72. ZHAO J, Xue E, Zhou S, Zhang M, et al
    Allostatic Load, Genetic Susceptibility, Incidence Risk, and All-cause Mortality of Colorectal Cancer.
    J Natl Cancer Inst. 2024 Sep 13:djae223. doi: 10.1093.
    >> Share

  73. GARG A, Damgacioglu H, Sigel K, Nyitray AG, et al
    Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035.
    J Natl Cancer Inst. 2024;116:1508-1512.
    >> Share

  74. DESHMUKH AA, Lin YY, Damgacioglu H, Shiels M, et al
    Recent and projected incidence trends and risk of anal cancer among people with HIV in North America.
    J Natl Cancer Inst. 2024;116:1450-1458.
    >> Share

    August 2024
  75. CHENG E, Ou FS, Gatten C, Ma C, et al
    Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer.
    J Natl Cancer Inst. 2024 Aug 30:djae213. doi: 10.1093.
    >> Share

  76. BROWN JC, Ma C, Shi Q, Couture F, et al
    Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Natl Cancer Inst. 2024 Aug 24:djae203. doi: 10.1093.
    >> Share

  77. LIANG PS, Bhatt D
    Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key.
    J Natl Cancer Inst. 2024 Aug 8:djae176. doi: 10.1093.
    >> Share

  78. RIM SH, Beer L, Saraiya M, Tie Y, et al
    Prevalence of anal cytology screening among persons with HIV and lack of access to high-resolution anoscopy at HIV care facilities.
    J Natl Cancer Inst. 2024;116:1319-1332.
    >> Share

  79. GUPTA A, O'Callaghan CJ, Zhu L, Jonker DJ, et al
    The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17.
    J Natl Cancer Inst. 2024;116:1313-1318.
    >> Share

  80. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    >> Share

  81. BERRY E, Hostetter J, Bachtold J, Zamarripa S, et al
    Evaluating colonoscopy quality by performing provider type.
    J Natl Cancer Inst. 2024;116:1264-1269.
    >> Share

    July 2024
  82. ALAGOZ O, May FP, Doubeni CA, Fendrick AM, et al
    Impact of racial disparities in follow-up and quality of colonoscopy on colorectal cancer outcomes.
    J Natl Cancer Inst. 2024 Jul 24:djae140. doi: 10.1093.
    >> Share

    June 2024
  83. TSAI YY, Nair KG, Barot SV, Xiang S, et al
    Differences in Tumor-Associated T cell receptor repertoires between Early-Onset and Average-Onset colorectal cancer.
    J Natl Cancer Inst. 2024 Jun 20:djae143. doi: 10.1093.
    >> Share

  84. SONG Y, Loomans-Kropp H, Baugher RN, Somerville B, et al
    Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome.
    J Natl Cancer Inst. 2024;116:957-965.
    >> Share

  85. YATES J, Schaufelberger H, Steinacher R, Schar P, et al
    DNA-methylation variability in normal mucosa: a field cancerization marker in patients with adenomatous polyps.
    J Natl Cancer Inst. 2024;116:974-982.
    >> Share

  86. RANSOHOFF DF
    Evaluating a blood test for Colon cancer screening: how simulation modeling can inform clinical policy making and research.
    J Natl Cancer Inst. 2024 Jun 6:djae125. doi: 10.1093.
    >> Share

  87. NASCIMENTO DE LIMA P, Van Den Puttelaar R, Knudsen AB, Hahn AI, et al
    Characteristics of a cost-effective blood test for colorectal cancer screening.
    J Natl Cancer Inst. 2024 Jun 6:djae124. doi: 10.1093.
    >> Share

    May 2024
  88. HOCHSTER HS, Catalano P, Weitz M, Mitchell EP, et al
    Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).
    J Natl Cancer Inst. 2024 May 22:djae114. doi: 10.1093.
    >> Share

  89. CORONADO GD, Bienen L, Burnett-Hartman A, Lee JK, et al
    Maximizing scarce colonoscopy resources: the crucial role of stool-based tests.
    J Natl Cancer Inst. 2024;116:647-652.
    >> Share

    April 2024
  90. SUN J, Zhao J, Zhou S, Li X, et al
    Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer.
    J Natl Cancer Inst. 2024 Apr 22:djae089. doi: 10.1093.
    >> Share

  91. FANG A, Ugai T, Gurjao C, Zhong R, et al
    Alcohol and colorectal cancer risk subclassified by mutational signatures of DNA mismatch repair deficiency.
    J Natl Cancer Inst. 2024 Apr 4:djae078. doi: 10.1093.
    >> Share

    March 2024
  92. BEVER AM, Hang D, Lee DH, Tabung FK, et al
    Metabolomic signatures of inflammation and metabolic dysregulation in relation to colorectal cancer risk.
    J Natl Cancer Inst. 2024 Mar 1:djae047. doi: 10.1093.
    >> Share

  93. GOPALANI SV, Saraiya M, Huang B, Tucker TC, et al
    Population-level incidence of HPV-positive oropharyngeal, cervical, and anal cancers by smoking status.
    J Natl Cancer Inst. 2024 Mar 1:djae054. doi: 10.1093.
    >> Share

    October 2023
  94. HAAS CB, Engels EA, Horner MJ, Pfeiffer RM, et al
    Cumulative incidence of anal cancer since HIV or AIDS diagnosis in the United States.
    J Natl Cancer Inst. 2023;115:1227-1230.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016